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Aim: To assess the real contribution of modern radiation therapy (RT) technology in the more
common tumoral types in Central America, Caribbean and South America.
Background: RT is an essential tool in the management of cancer. RT can be either palliative or
of  curative intent. In general, for palliative radiotherapy, major technologies are not needed.
Materials and methods: We  analyzed the contribution of RT technology based on published
evidence for breast, lung, gastric, gallbladder, colorectal, prostate and cervix cancer in terms
of  disease control, survival or toxicity with especial focus on Latin America.
Results: Findings indicate that three dimensional conformal radiation therapy (3D RT) is
the  gold standard in most common type of cancer in the studied regions. Prostate cancer is
probably the pathology that has more beneﬁts when using new RT technology such as inten-
sity  modulated radiation therapy (IMRT) versus 3DRT in terms of toxicity and biochemical
progression-free survival.
Conclusions: In light of the changes in technology, the ever-increasing access of developingcountries to such technology, and its current coverage in Latin America, any efforts in this
area should be aimed at improving the quality of the radiotherapy departments and centers
that are already in place.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
of cervix cancer. In the zone of the Caribbean there is.  Background
he radiotherapy (RT) is an essential tool in the handling of
ancer. From the discovery of the X-rays, the RT has evolved
ery much as for the comprehension of his functioning, jus-
iﬁcation and form of use, generating articles of high quality
nvestigation. During the natural history of the cancer, about
0% of the patients will need RT during the course of his
llness, this needs changes in percentage, depending on the
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tumor type that has the patient, his stage and form of presen-
tation and of the population proﬁle in which we  are.1
If we analyze the region of Central America, Caribbean
and South America, the cancer is the second cause of
death,2 having 75% of the countries programs of alertness
of cancer. However, only 25% have programs of screening
2io Medicine IRAM, Av. Americo Vespucio 1314, Vitacura, Santiago,
one radiotherapist and 1.4 machines of RT every 1.6 mil-
lion persons versus 9 radiotherapists and 6.4 machines every
1.6 million persons in the developed countries.2 In 2008 in
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Incidence and mortality of cancer in Southern America.the region of Central America, Caribbean and South Amer-
ica there was an incidence of cancer of 1,011,000 of cases
(4,89,000 men  versus 5,22,000 women) and a mortality of
5,89,000 cases (3,02,000 men  versus 2,87,000 women).2 The
most common cancer incidences in men, in decreasing order,
are prostate, lung, gastric and colorectal, being the higher
mortality for lung cancer, followed by prostate, gastric and
colorectal (Fig. 1). The most common incidences in women,
in decreasing order, are breast, cervix, colorectal, gastric
and lung, being the most higher mortality for breast can-
cer, continued of cervix, gastric, lung and colorectal cancer
(Fig. 1).
For the particular case of Chile,3 the most common cancer
incidences in men, in decreasing order, are prostate, gas-
tric, lung, colon and gallbladder, being the higher mortality
for gastric cancer, followed by prostate, lung, gallbladder and
colon (Table 1). The most common incidences in women, in
decreasing order, are breast cancer, gallbladder, cervix, gas-
tric, colon and lung, being the higher mortality for gallbladder
cancer, followed by breast, gastric, lung, cervix and colon
(Table 1).
RT can be either palliative or of curative intent. In gen-
eral, for palliative radiotherapy, major technologies are not
needed. The objective of this review is to assess the evidence-
based contribution of the technology in the most common
type of cancers in the region of Central America, Caribbean
and South America, with emphasis on the Chilean popula-
tion.2.  Evidence  based  radiation  oncology
according  to  location
2.1.  Breast  cancer
The RT has a clear roll in the handling of in situ and inﬁltrative
breast cancer.4
We  know that the RT in the ductal in situ carcinoma, on
having been added to the conservative surgery, diminishes
the ipsilateral recurrence, with a beneﬁt of 15.2% to 10 years
(p < 0.00001),5 without a beneﬁt in the overall survival or some
increase of mortality for cardiac and pulmonary toxicity to
10 years (p = NS).5 For inﬁltrative breast carcinoma, the RT, on
having been added to the conservative surgery, gives a bene-
ﬁt in overall survival to the speciﬁc deaths caused by breast
cancer of 3.8% to 15 years (p = 0.0001).6 On having been added
to the entire Mastectomy, in inﬁltrative breast carcinoma, in
patients N (−), it gives a detriment in overall survival to the
speciﬁc deaths caused by breast cancer of 3.6% to 15 years
(p = 0.01) and an increase in the incidence of counter side can-
cers of breast in a 1.8% to 15 years (p = 0.002).7 But in patients N
(+), the RT post entire mastectomy, in inﬁltrative breast cancer,
gives a beneﬁt in overall survival to the speciﬁc deaths caused
by breast cancer of 5.4% to 15 years (p = 0.0002).7The problem is that the RT in inﬁltrative breast cancer,
produces an increase in the mortality in the deaths not
related to breast cancer of 0.5% and 1.3% to 10 and 15 years
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 259–266 261
Table 1 – Estimated mortality from cancer in different locations in men  and women (Chile 2003–2007).
Men  Women
Location No. of
cases/year
CI 95% No. of
deaths/year
Location No. of
cases/year
CI 95% No. of
deaths/year
Prostate 4098 3919–4284 1538 Breast 3791 3587–4017 1128
Gastric 2388 2245–2520 2062 Gallbladder 1531 1417–1647 1344
Lung 1373 1276–1467 1475 Cervix uteri 1279 1167–1384 667
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espectively (p = 0.001),7 this attributed largely to the cardiac
oxicity, which is major of the left side, but bearing in mind
hat this information collaborates to RT of ancient skill (Ortho-
oltaje, 2D), it reaches port signiﬁcantly with major mortality
o 10 and 15 years after the RT in the period of 1973–1982,8
hen without major cardiac toxicity in the period of 1983–1992
nd 1993–2001, which is when8 becomes massive the skill
f 3D RT. Knowing that the new technologies as the IMRT
o not contribute a beneﬁt in survival in these patients, per-
aps this roll this one in diminishing the toxicity. If we know
hat to homogenize the dose we have wedges, compensat-
ng skin, intensity modulated of forward planning or intensity
odulated of inverse planning. But, more  than the homo-
eneity of the dose, what more  it is going to inﬂuence the
ate toxicity the mammary  tissue it is going to be the size
f the breast, the cosmetics pre RT, post operative infections
nd use of tobacco, which are independent factors to the
echnology.
.2.  Lung  cancer
he RT has his role in lung cancer as much of small cells
SCLC) as non small cells lung cancer (NSCLC). In NSCLC,
he cancer presents to itself in stages I in 24%, the II in 7%,
he III in 31%, the IV in 38%.9 The standard of treatment in
tage I and II is the surgery, be already lobectomy or pneu-
onectomy with mediastinal lymph node sampling, the RT
as curative intensity in this case when the patient is med-
cally unoperable. Since we  know that the post operative RT
or the stages I and II gives a detriment in the survival and for
ore  advanced stages so much combined with chemotherapy
CT) or of exclusive form it does not contribute in survival,10
ut when we  realize 3D RT, dose escalated, without nodal elec-
ive irradiation of mediastinum,11–14 with restriction of dose
o organ healthy lung, a beneﬁt exists in the local control and
urvival in these patients, with a low index of pneumonitis,
urning feasible the treatment. Another treatment that has
howed excellent results in stage I is the stereotactic abla-
ive RT (SBRT), reaching a local control for 2 years of 95%
n patients T1-2 treated with 3 fractions of 20–21 Gy and a
urvival of 66.6%.15 But for this special skill of RT15 needs
 rigorous planning, dosimetry, measurement, immobiliza-
ion and advanced cross-check of. The good of this skill is
hat there would not be difference his result versus surgery,16hich turns out to be tantalizing at the time of realizing it, but
as to still be proved in a Phase III study. For the stage III of
ung, the combination of Surgery and RT + CT versus RT + CT
as failed in showing beneﬁt,17,18 but the RT + CT based onGastric 1173 1072–1273 1025
Colon 877 782–968 586
Lung 815 732–899 817
Cisplatin versus the exclusive RT, has showed beneﬁt in the
events free survival of 6% and 3.5% to 2 and 6 years respectively
and overall survival of 4% and 2.2% to 2 and 5 years in the ran-
domized controlled trials and meta analyses,19–23 all of them
realized with conventional technology of 3D RT, transform-
ing in the gold standard of treatment, where there still does
not remain clear the roll of the new technologies, which must
be proved inside Phase III studies, where at least they must
show a descent in the toxicity, who understands esophagitis,
nausea, vomiting, neutropenia of 8–32%24,25 for the conven-
tional technology. In SCLC, the RT + CT is the standard of
treatment in limited illness, including elective irradiation of
the mediastinum, with a survival of 20–26% to 5 years,26
which is demonstrated in the later meta analyses with con-
ventional technology of 3D RT and CT based on Cisplatin and
Etoposide.27
2.3.  Gastric  cancer
The RT and CT, for patients loco regionally advanced (cT3–4,
N0–1, M0), based on 5FU they have adjuvant roll in the
handling of gastric cancer, considered standard from the
publication of the INT 0116, with a beneﬁt in the median
of overall survival for the group of surgery plus RT + CT of
36 months versus 27 months for surgery alone (p = 0.005),28
beneﬁted that it is supported in its update with 10 years
of pursuit with a beneﬁt in the median of overall survival
for the group of surgery plus RT + QT of 35 months versus
27 months for surgery alone (p = 0.0046).29 This treatment
is based on a 3D RT, retrospective Chilean studies show a
comparable result,30,31 without the need for a major technol-
ogy.
2.4.  Gallbladder  cancer
The roll of the RT in this ﬁeld of the oncology still remains
uncertain, although there exist works32 that show that when
RT is added to 3D RT to the surgery, in patients loco region-
ally advanced (T2–3, N0–1, M0), the median survival increases
from 8 to 14 months (p < 0.001), this is veriﬁed also by other
authors33,34 than when the RT is added to the surgery, a ben-
eﬁt exists in the overall survival (HR = 0.78, 95% IC 0.70–0.87,
p < 0.01), which is major in the patients with positive lymph
nodes (HR = 0.65, 95% IC 0.54–0.79, p < 0.01). Also there exists
a meta analyses35 that shows beneﬁt for the adjuvant RT+CT
versus surgery alone (OR, 0.33; 95% IQ, 0.14–0.81; p = 0.01) in
R1 operated Gallbladder cancer, and an uncertain beneﬁt for
the operated patients R0 with positive nodes respectively (OR,
d rad262  reports of practical oncology an
1.26; 95%CI, 0.88–1.79; p = 0.20). In the Chilean literature, where
the treatment that there considers to be standard who con-
sists of a simple cholecystectomy for initial tumors (that they
invade up to the proper muscular layer) and then extended
with node dissection when the tumor invades even subserous
plus 3D RT + CT based on Fluoropyrimidines, national series,36
with loco regionally advanced patients, that receive the treat-
ment, they reach 57% of overall survival to 5 years, without
major need of technology.
2.5.  Colorectal  cancer
The rectal cancer born under the sigmoid reﬂection and it
spreads up to the anal channel, separating it from the colon
cancer, entity to which we will not refer in this article. The RT is
the standard treatment in loco regionally advanced rectal can-
cer (cT3–4 or cTanyN1–2, M0), it is possible to base in diverse
neoadjuvant or adjuvant schemes of treatment. The neoad-
juvant treatment includes pre operative RT of short course,
25 Gy in 5 fractions followed by immediate surgery, or long
course, 50.4 Gy in 25–28 fractions and then surgery in 4–8
weeks. The latter scheme must always go accompanied by CT
based on ﬂuoropyrimidines. The advantage of long versus the
short one is that it leaves one major chance of downsizing
including major pathological complete responses, improving
the resection capability, although this did not translate into
a higher sphincter preservation rate and no statistically sig-
niﬁcant differences were observed in disease free survival or
overall survival.37,38 Nevertheless, the scheme of short course
is equivalent to the long scheme in the tumors where the
downsizing is not needed or that do not have commitment of
the mesorectal fascia. When compares pre operative RT + CT
followed by adjuvant CT versus post operative RT + QT, it has
been demonstrated that the ﬁrst one signiﬁcantly reduces the
risk of local recurrence, it has less sharp and long-term tox-
icity, allows a major preservation and sphincter function in
low rectal tumors.39–41 Nevertheless, does not exist beneﬁt
in distance control and overall survival of a scheme versus
other.39–41
The adjuvant treatment includes RT + CT followed by adju-
vant CT for patients who  did not receive the pre operatively
treatment,42–46 based on the long scheme of treatment of
50.4 Gy in 25–28 concomitant fractions with CT based on ﬂu-
oropyrimidines. The potential advantage of this treatment
versus the preoperative treatment is to be provided with a bet-
ter selection of the patients based on the pathological study.
The disadvantages include increase of the toxicity of small
bowel or of the scar after an abdomino perineal resection
(APR) and potentially major radio resistance in the ﬁeld for
hypoxic cells in the post surgical area. In a small study of APR
randomize to early RT + CT versus late RT + QT, and the early
group achieved a better disease free survival to 10 years (63%
versus 40%; p = 0.043), therefore it is necessary to give early
post operative RT + CT to those who had indication of pre oper-
ative RT + CT.44 All the included schemes of treatment that
include RT were realized based on 3D RT. It seems that fur-
ther investigation with novel technology is needed in order
to know the beneﬁt of more  conformal therapies especially in
terms of toxicity.iotherapy 1 9 ( 2 0 1 4 ) 259–266
2.6.  Prostate  cancer
The prostate cancer, considering this one in its curative stage
(T1–4, N0, M0), according to 3 risk groups of metastatic disease,
these factors get together with the examination of prostate
palpation, PSA levels in blood and the Gleason score of the
prostate biopsy; that of low risk (T1–2a, less PSA to 10, less
or equal Gleason to 6), intermediate risk (T2b–2c, PSA 10–20,
equal Gleason to 7), high risk (T3a–4, Gleason 8–10, PSA > 20).
The contribution of the RT is present in these 3 risk groups.
For the low risk group, the curative alternatives includes radi-
cal prostatectomy, external beam RT and brachytherapy with
a cancer speciﬁc survival of 100% to 10 years46,47 For the inter-
mediate risk group, the curative alternatives include radical
prostatectomy, external beam RT plus neoadjuvant hormonal
treatment (LHRHa) for 3–6 months.47,48 For the high risk group,
the curative alternatives include radical prostatectomy, exter-
nal beam RT plus neoadjuvant hormonal treatment (LHRHa)
for 3–6 months and then adjuvant for 2 years.47,48 It is recom-
mended post operative RT, that shows beneﬁt in terms of PSA
fail and beneﬁt in survival, in patients of high risk, and sal-
vataje RT in patients who present biochemical failure during
its PSA monitoring, with a demonstrated survival beneﬁt, but
with a signiﬁcant increase of the genitourinary, intestinal and
sexual complications.47,48
As for the skills of RT, the IMRT  versus 3D RT signiﬁ-
cantly reduces the gastro intestinal complications.49,50 This
skill would allow a surer scaling of dose, where it has been
proved that this one delivers a beneﬁt in disease free sur-
vival of biochemical and clinical progression.51–54 As for the
RT dose, the doses for low risk must be to 75.6–79.2 Gy in low
risk group and on 81 Gy for intermediate and high risk.49,55,56
Another sure way of dose escalation, if it is that he does not
get ready of IMRT but if of high dose rate brachytherapy of
valuation, it is with hypofractionated 3D RT combined with
the last one, which demonstrates a beneﬁt in the disease free
survival versus hypofractionated 3D RT alone, with similar
genitourinary and gastro intestinal toxicity.57
2.7.  Cervix  cancer
The treatment of cervix cancer according to the FIGO clinical
classiﬁcation,58 which depends on the stage, includes surgery,
RT and RT + CT. For the stage IA only needs surgery,59–61 and
external beam RT plus brachytherapy is reserved in medically
unoperable patients.62 For the stages IB and IIA can be treated
with surgery with lymph node dissection or external beam
RT plus brachytherapy, which are the same way effective59–61
Only a randomized study compares them, its overall survival
and disease free survival to 5 years it is 83% and 74% respec-
tively, taking into account that 66% of the patients of the
surgical arm, with risk factors, received adjuvant RT, what
increased the severe complications 28% for the surgical arm
versus 12% of the RT arm.63 For stages IIB to IVa, the RT + CT
plus brachytherapy is the gold standard treatment,58–60 with
a local control of 88–95% IB, 70–80% IIB, 30–40 III and a 5
years survival higher than 80% IB, 65% IIB and 40% III.64,65
The treatment of external beam RT, includes the pelvis with
dose of 45 Gy, in addition to the boost to the positive lymph
nodes areas or positive surgical margins. In absence of positive
radio
l
t
c
a
o
r
i
a
R
a
d
G
o
t
N
o
w
a
H
w
9
t
i
w
i
o
i
i
l
c
d
d
i
b
t
d
a
M
v
s
o
t
t
3
W
a
d
c
t
o
p
a
m
c
g
areports of practical oncology and 
ymph nodes, the top of the ﬁeld must be even L4–L5 or up to
he aortic fork.59–61 The form of external beam RT, has not been
ompared in randomized studies. Retrospective reviews show
 low coverage of the lymph nodes based on the bony points
f the 2D RT. The IMRT  does not recommend to itself of given
outine the motility of the organs, for what is surer to real-
ze with 3D RT.59–61 For the treatment of positive lymph nodes
nd parametrial involvement, the ideal dose of external beam
T to sterilize them, preferred by most of the clinical ones, is
round 60 Gy.59–61 It is not clear that the surgical debulking or
ose escalation improves the survival in these patients, since
rigsby et al.66 concluded that these patients develop more
ften a distance failure, indiscriminately of the dose escala-
ion or local surgery. For the treatment of CT, in 1999 the U.S.
ational Cancer Institute publishes an alert that the CT based
n Cisplatin, added to RT, improves the survival in patients
ith cervix cancer stages IIB to IVa, based on 5 Randomized tri-
ls released simultaneously.67–71 This treatment would have a
R in favor of the CT arm for the risk of recurrence of 0.54–0.74,
ith an increase in the disease free survival of 8% to 5 years,
% in the loco regional disease free survival and of 7% in
he metastases disease free survival, advantage that spreads
nclusive for the regimens that do not contain Cisplatin.72 The
orld CT standard is not yet deﬁnite, but the most used reg-
men is Cisplatin 40 mg/m2 weekly for 5–6 weeks, reserving
ther regimens in cases of intolerance to the Cisplatin or renal
llness.72
In addition to the external beam RT, the ideal handling
ncludes brachytherapy with dose of 80–90 bioequivalent Gy to
ow dose rate brachytherapy (LDR) to the point A or high risk
linical volume,59–61 this treatment must be carried out <50–55
ays of initiated not to compromise the result.73 Difference
oes not exist in overall survival, local control, long-term tox-
city between the low dose rate (LDR) and high dose rate (HDR)
rachytherapy for stages I–III.59–61 It is possible to use intersti-
ial brachytherapy in the cases with bulky illness, anatomical
istortion, vaginal extension.74,75 Probably one of the best
dvances to date related to technology is the administration of
RI-3D guided brachytherapy which allows for not only target
olumes reduction but also improve local control and overall
urvival versus the historical Vienna series.76 In cases in which
ne does not count with brachytherapy, it is possible to give
he boost with external beam RT with dose of 64–75 Gy, trying
o protect to the maximum nearby organs.59
.  Discussion
e  know that in the region of Central America, Caribbean
nd South America cancer is the second leading cause of
eath,2 these regions belong to the axis of the developing
ountries, therefore, the strategy to ﬁght cancer in our coun-
ries, as says the World Cancer Report 20082 should be based
n surveillance, primary prevention, secondary prevention,
roper diagnosis and treatment, whereas in the latter surgery
nd the possibility of access to RT and CT, and a palliative care
anagement, whereas only 75% of countries in the area have
ancer surveillance programs, only 25% have screening pro-
rams for cervix uteri cancer and in the Caribbean area there
re 1 Radiotherapist and 1.4 Radiotherapy machines every 1.6therapy 1 9 ( 2 0 1 4 ) 259–266 263
million people versus 6.4 Radiotherapists and 9 Radiotherapy
machines every 1.6 million people in developed countries.2
Based on this brief review of the evidence and the con-
tribution of technology to the most common tumor types in
Central America, Caribbean and South America with a par-
ticular emphasis on the Chilean population, the ﬁndings in
terms of disease control, survival, toxicity reduction, and bet-
ter accuracy of the treatments can be summarizes at follows.
In situ breast cancer simply adding 3D RT adds a beneﬁt in
reducing ipsilateral recurrences,5 in inﬁltrating breast cancer
simply adding 3D RT after conservative surgery confers a ben-
eﬁt in overall survival6 and 3D RT in post mastectomy patients
with positive lymph nodes gives a survival beneﬁt in speciﬁc
deaths from breast cancer.7
In non small cell lung cancer, 3D RT dose escalation in stage
I and II medically inoperable without elective nodal irradiation
of mediastinum shows a beneﬁt in local control and survival in
these patients,11–14 and ablative SBRT for stage I, which have
not yet results being compared to surgery in a Phase III study.
For stage III, 3D RT plus CT based on cisplatin versus exclu-
sive RT has shown beneﬁt in event-free survival and overall
survival in randomized trials and meta-analyzes.19–23 Small
cell Lung cancer, 3D RT and CT is the standard treatment for
limited disease, including elective mediastinal irradiation,26
which is demonstrated in the subsequent meta-analysis with
conventional 3D RT and CT based on cisplatin and etoposide.27
In gastric cancer, 3D RT in conjunction with CT based on
5FU for loco regionally advanced patients (cT3–4, N0–1, M0)
is considered standard since publication of INT 0116, with a
beneﬁt in median overall survival for the surgery group with
RT + CT versus surgery alone,28 a beneﬁt that is held in updat-
ing with 10 years of follow up.29 Where Chilean retrospective
studies show comparable results.30,31
In gallbladder cancer the role of 3D RT remains uncertain,
although there are studies32 showing that when adding 3D RT
to surgery in patients loco regionally advanced (T2–3, N0–1,
M0)  increases the median survival, this will also checked by
other authors33,34 that when adding RT to surgery, there is a
beneﬁt in overall survival, higher in the presence of positive
lymph nodes. There is also a meta-analysis35 showing beneﬁt
for adjuvant RT + CT versus surgery alone in gallbladder cancer
operated R1, and an uncertain beneﬁt for patients with posi-
tive lymph nodes operated R0 respectively. In Chileans studies
who received extended cholecystectomy for tumors invading
to the subserosa with lymph node dissection, the addition of
3D RT plus ﬂuoropyrimidine based CT, national series achieved
a 57% overall survival at 5 years.36
For rectal cancer patients loco regionally advanced (cT3–4
or o cTanyN1–2, M0) 3D RT is an essential part of the treat-
ment of this condition, when doing so may be preoperative
neoadjuvant short course, 25 Gy in 5 fractions followed by
immediate surgery, or long course, 50.4 Gy in 25–28 fractions
Concomitant CT and then surgery in 4–8 weeks, with the lat-
ter potentially better to reduce the risk of local recurrence and
improve survival.37–39 When comparing preoperative RT + CT
followed by adjuvant CT versus post operative RT + CT, we  see
that both schemes have the same overall survival, but greater
toxicity post operative regimen.39–41
In prostate cancer, in its curative stage, the RT indica-
tion is present in the 3 risk groups. About radiation mode,
d rad
r
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IMRT  versus 3D RT signiﬁcantly reduces gastrointestinal
complications.49,50 This technique would allow a safer dose
escalation, where it has been proven that this provides a ben-
eﬁt in clinical and biochemical progression-free survival.51–54
As the dose of RT, for low risk prostate cancer should be
75.6–79.2 Gy in conventional fractionation and 81 Gy for inter-
mediate and high risk.49,55,56 In the case of not having IMRT,
can be escalate dose with hypo fractionated 3D RT and HDR
brachytherapy, which shows a beneﬁt in recurrence-free sur-
vival versus hypo fractionated 3D RT alone, with similar
urinary and gastrointestinal toxicity.57
In cervix cancer, the handling of RT and Brachytherapy
encompasses all stages, for stage IA reserves external beam
RT plus brachytherapy in medically inoperable patients62 for
stage IIB–IVa, 3D RT with concurrent CT plus brachytherapy is
the gold standard treatment,59–61 with a 88–95% local control
IB, IIB 70–80%, 30–40 III and a 5-year survival greater than 80%
IB, IIB 65% and 40% III,64,65 which can be improved with the
use of MRI  adaptive brachytherapy combined with 3DCRT.76 As
for the type of external beam RT, retrospective reviews show
a lower level of coverage to the lymph nodes based on bony
points of 2D RT. The IMRT routine is not recommended due to
the great motility of the organs, so that is safer realize it with
3D RT.59–61
4.  Conclusions
In light of the changes in technology, the ever-increasing
access of developing countries to such technology, and its cur-
rent coverage in Latin America, any efforts in this area should
be aimed at improving the quality of the radiotherapy depart-
ments and centers that are already in place.
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